Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.72 |
| ▸ | NOD1 | Q9Y239 | 11/20 | 0.55 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13584158 | 1.00 | GLP1R (0.72) | GLP1RNOD1SLC6A5 | |
| SCHEMBL5954492 | 1.00 | GLP1R (0.72) | GLP1RNOD1SLC6A5 | |
| SCHEMBL14735663 | 0.96 | GLP1R (0.67) | GLP1RNOD1SLC6A5 | |
| SCHEMBL14735664 | 0.96 | GLP1R (0.67) | GLP1RNOD1SLC6A5 | |
| SCHEMBL4152876 | 0.93 | GLP1R (0.65) | GLP1RNOD1SLC6A5 | |
| SCHEMBL4004880 | 0.92 | GLP1R (0.63) | GLP1RNOD1 | |
| SCHEMBL15633597 | 0.92 | GLP1R (0.63) | GLP1RNOD1 | |
| SCHEMBL4541595 | 0.92 | GLP1R (0.63) | GLP1RNOD1 | |
| SCHEMBL4561886 | 0.92 | GLP1R (0.63) | GLP1RNOD1 | |
| SCHEMBL2181197 | 0.92 | GLP1R (0.63) | GLP1RNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3548062-B1 | NEW COMPOUNDS AS PEPTIDIC GLP1/GLUCAGON/GIP RECEPTOR AGONISTS | SANOFI SA (FR) | 2022-01-12 | — | — | EP | claimed |
| EP-3548508-B1 | NEW COMPOUNDS AS PEPTIDIC TRIGONAL GLP1/GLUCAGON/GIP RECEPTOR AGONISTS | SANOFI SA (FR) | 2021-10-27 | — | — | EP | claimed |
| EP-3548062-A1 | NEW COMPOUNDS AS PEPTIDIC GLP1/GLUCAGON/GIP RECEPTOR AGONISTS | Sanofi (FR) | 2019-10-09 | — | — | EP | claimed |
| EP-3548508-A1 | NEW COMPOUNDS AS PEPTIDIC TRIGONAL GLP1/GLUCAGON/GIP RECEPTOR AGONISTS | Sanofi (FR) | 2019-10-09 | — | — | EP | claimed |
| EP-3129397-B1 | PEPTIDIC DUAL GLP-1 / GLUCAGON RECEPTOR AGONISTS DERIVED FROM EXENDIN-4 | SANOFI SA (FR) | 2019-01-09 | — | — | EP | claimed |
| EP-3129395-B1 | EXENDIN-4 DERIVATIVES AS PEPTIDIC DUAL GLP-1 / GLUCAGON RECEPTOR AGONISTS | SANOFI SA (FR) | 2018-12-19 | — | — | EP | claimed |
| WO-2018100134-A1 | NEW COMPOUNDS AS PEPTIDIC TRIGONAL GLP1/GLUCAGON/GIP RECEPTOR AGONISTS | SANOFI (FR) | 2018-06-07 | — | — | WO | claimed |
| WO-2018100135-A1 | NEW COMPOUNDS AS PEPTIDIC GLP1/GLUCAGON/GIP RECEPTOR AGONISTS | SANOFI (FR) | 2018-06-07 | — | — | WO | claimed |
| US-20180155406-A1 | COMPOUNDS AS PEPTIDIC TRIGONAL GLP1/GLUCAGON/GIP RECEPTOR AGONISTS | SANOFI (FR) | 2018-06-07 | — | — | US | claimed |
| US-20180155407-A1 | COMPOUNDS AS PEPTIDIC GLP1/GLUCAGON/GIP RECEPTOR AGONISTS | SANOFI (FR) | 2018-06-07 | — | — | US | claimed |
| EP-3129396-A1 | DUAL GLP-1 / GLUCAGON RECEPTOR AGONISTS DERIVED FROM EXENDIN-4 | Sanofi (FR) | 2017-02-15 | — | — | EP | claimed |
| EP-3129395-A1 | EXENDIN-4 DERIVATIVES AS PEPTIDIC DUAL GLP-1 / GLUCAGON RECEPTOR AGONISTS | Sanofi (FR) | 2017-02-15 | — | — | EP | claimed |
| EP-3129397-A1 | PEPTIDIC DUAL GLP-1 / GLUCAGON RECEPTOR AGONISTS DERIVED FROM EXENDIN-4 | Sanofi (FR) | 2017-02-15 | — | — | EP | claimed |
| US-20150322128-A1 | DUAL GLP-1/GLUCAGON RECEPTOR AGONISTS DERIVED FROM EXENDIN-4 | SANOFI (FR) | 2015-11-12 | — | — | US | claimed |
| US-20150322129-A1 | PEPTIDIC DUAL GLP-1/GLUCAGON RECEPTOR AGONISTS DERIVED FROM EXENDIN-4 | SANOFI (FR) | 2015-11-12 | — | — | US | claimed |
| US-20150315260-A1 | EXENDIN-4 DERIVATIVES AS PEPTIDIC DUAL GLP-1/GLUCAGON RECEPTOR AGONISTS | SANOFI (FR) | 2015-11-05 | — | — | US | claimed |
| WO-2015155141-A1 | PEPTIDIC DUAL GLP-1 / GLUCAGON RECEPTOR AGONISTS DERIVED FROM EXENDIN-4 | SANOFI (FR) | 2015-10-15 | — | — | WO | claimed |
| WO-2015155140-A1 | DUAL GLP-1 / GLUCAGON RECEPTOR AGONISTS DERIVED FROM EXENDIN-4 | SANOFI (FR) | 2015-10-15 | — | — | WO | claimed |
| WO-2015155139-A1 | EXENDIN-4 DERIVATIVES AS PEPTIDIC DUAL GLP-1 / GLUCAGON RECEPTOR AGONISTS | SANOFI (FR) | 2015-10-15 | — | — | WO | claimed |
| EP-2057189-B1 | ACYLATED EXENDIN-4 COMPOUNDS | NOVO NORDISK AS (DK) | 2013-03-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322128-A1 | DUAL GLP-1/GLUCAGON RECEPTOR AGONISTS DERIVED FROM EXENDIN-4 | GLP1R, GIPR, GCGR | GLP1R 1/4885NOD1 1462/4885SLC6A5 887/4885 |
| US-20150315260-A1 | EXENDIN-4 DERIVATIVES AS PEPTIDIC DUAL GLP-1/GLUCAGON RECEPTOR AGONISTS | GLP1R, GIPR, GCGR | GLP1R 1/4885NOD1 1055/4885SLC6A5 1327/4885 |
| US-20180155406-A1 | COMPOUNDS AS PEPTIDIC TRIGONAL GLP1/GLUCAGON/GIP RECEPTOR AGONISTS | GLP1R, GIPR, GCGR | GLP1R 1/4885NOD1 1688/4885SLC6A5 1720/4885 |
| US-20150322129-A1 | PEPTIDIC DUAL GLP-1/GLUCAGON RECEPTOR AGONISTS DERIVED FROM EXENDIN-4 | GLP1R, GIPR, GCGR | GLP1R 1/4885NOD1 1301/4885SLC6A5 1366/4885 |
| US-20180155407-A1 | COMPOUNDS AS PEPTIDIC GLP1/GLUCAGON/GIP RECEPTOR AGONISTS | GLP1R, GIPR, GCGR | GLP1R 1/4885NOD1 1771/4885SLC6A5 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.